News & Events

IMPEL NEUROPHARMA ANNOUNCES PRIMARY OBJECTIVES MET IN PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE

Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes…

Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams’ Role Expanded To Chairman and CEO

SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of…

Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs – Migraine Franchise

January 16, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K.…

2 3 4